PHOENIX — A company based in Taiwan that creates 3D pathology services and platforms to help cancer researchers is setting up a new lab in Phoenix.
JelloX Biotech Inc. will open its facility inside a biotechnology corridor called the Discovery Oasis across from the Mayo Clinic at 5777 E. Mayo Blvd.
The company’s research base in Phoenix will be 1,100 square feet.
What’s unique about JelloX research base in Phoenix?
It will house some of the company’s most advanced equipment, which allow for AI analysis and 3D imaging, according to Dr. Yen-Yin Lin, the CEO of JelloX.
“With all the promise 3D pathology offers, we are thrilled to establish a research base in the US, particularly one where we can work hand-in-hand with other pioneering companies to fight cancer while contributing to the country’s leadership in biotech innovation,” Lin said in a Monday news release.
He said 3D pathology can give researchers 50 times more information than traditional 2D methods. This way, pathologists can more comprehensively understand a cancer patient’s tumor.
“The power of such a diagnostic tool lies in its ability to help pathologists stratify and personalize, matching the right patients with the right treatment at the right time,” Lin said. “This ultimately leads to better prognosis, quality of life, and more patient-centered care.”
The news of JelloX coming to Phoenix comes one year after a Taiwanese delegation of bioscience industry leaders toured Discovery Oasis and other local advanced medical technology facilities.
The post Taiwan-based JelloX Biotech to open US research base in Phoenix appeared first on KTAR.
